Doxazosin-structure.jpg (Doxazosin Structure)
Doxazosin Tablet
Product Images NDC 50090-0701
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Doxazosin (NDC 50090-0701). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure1.jpg (Figure1)
Label Image (Lbl500900701)
Not available. The text is too short and incomplete to generate a useful description.*
Label Image (Lbl500900704)
Product No. 5169-0 is a box of 30 tablets with a Lo7' logo and printed with the text "BOXAZOSTN 26". No further information is available.*
Label Image (Lbl500900706)
Label Image (Lbl500900734)
This appears to be a medication label or box. The product name may be "BoxazosTH" and it comes in a package with 36 tablets. It also appears to have a dosage of 8 mg.*
Table3.jpg (Table3)
This is a summary of the effectiveness data from placebo-controlled trials on the maximum flow rate and symptom score® rate (mL/sec). The table shows mean baseline change for placebo and doxazosin-treated patients. The efficacy was measured using the AUA questionnaire and the Modified Boyarsky Questionnaire, with a range of 0-30 and 7-39, respectively. Change is measured at the endpoint or fixed-dose efficacy phase, with varying hours post-dose for each study. Study 1 was conducted in hypertensives with BPH, and 35 patients received a dose of 8 mg doxazosin. The results show significant improvement in symptom score and maximum flow rate for doxazosin compared to placebo. The table also shows that in Study 2, titration to a fixed dose of doxazosin (2 mg or 4 mg) for 14 weeks resulted in a significant improvement in symptom score and maximum flow rate compared to placebo.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
